What are Boston Scientific's key growth drivers and strategies for the future?

Boston Scientific's growth strategy centers on improving patient care and healthcare delivery through the development and advocacy of less-invasive medical devices. Key drivers include product diversity, relentless innovation (both internal and through acquisitions), clinical excellence, operational efficiency, focused marketing, and active participation in the medical community. The company aims to capitalize on opportunities in specific therapeutic and diagnostic areas by investing in new technologies and expanding its product portfolio.

What is the status of Boston Scientific's drug-eluting stent (DES) program, particularly TAXUS?

The TAXUS™ drug-eluting stent program is a major focus for Boston Scientific. Early clinical trial results (TAXUS I) demonstrated promising safety and efficacy with zero percent thrombosis and zero percent restenosis. The company received FDA approval to initiate the TAXUS IV trial, designed to support U.S. commercialization. International market launches are planned for 2002, with a U.S. launch expected in late 2003, pending regulatory approval. This technology is considered crucial for addressing the challenge of in-stent restenosis.

How is the company addressing competition and pricing pressures in the medical device market?

Boston Scientific faces significant competition from major players like Medtronic, Johnson & Johnson, and others, as well as smaller, specialized companies. The company acknowledges increasing pressure on selling prices and potential margin compression due to managed care, economically motivated buyers, and healthcare cost containment efforts. To counter this, Boston Scientific emphasizes its ability to provide a broad product line from a single source, its commitment to innovation, product quality, physician familiarity, and cost-effective technology application. The company is also actively managing its product portfolio, including the declining NIR® stent sales, and focusing on newer, more advanced products like the Express™ and TAXUS™ stents.

What are the implications of the ongoing patent litigations for Boston Scientific?

Boston Scientific is involved in several patent litigations, including disputes concerning coronary stents and delivery systems with companies like Johnson & Johnson and Medtronic, as well as litigation with Medinol regarding the NIR® stent supply agreement. While the company believes its insurance coverage is adequate for product liability claims, adverse outcomes in patent litigation could result in significant liabilities, require costly licenses, or prevent the sale of certain products, potentially impacting financial condition and operations. The company is actively defending its intellectual property and engaging in legal proceedings, the outcomes of which carry inherent uncertainty and potential financial impact.

BSX 10-K FY2001 Annual Report — Revenue, Net Income, EPS

Summary

Boston Scientific Corporation's 2001 Form 10-K highlights a year of significant strategic growth, marked by key product developments and a robust acquisition strategy. The company, a leader in less-invasive medical devices, focused on expanding its portfolio across interventional cardiology, electrophysiology, gastroenterology, and other specialties. Significant progress was made with the launch of the Express™ coronary stent in international markets and advancements in the TAXUS™ drug-eluting stent program, which showed promising zero-restenosis and zero-thrombosis results in early trials. Financially, the company's growth has been fueled by both internal development and a series of strategic acquisitions in 2001, including those in electrophysiology, venous access, embolic protection, and oncology. These moves aim to solidify Boston Scientific's position as a comprehensive provider of less-invasive medical solutions. The report also details ongoing efforts in clinical trials to support new product approvals and market expansion, particularly for the TAXUS stent in the U.S. Investors should note the company's strong emphasis on innovation, clinical excellence, and operational efficiency as drivers for future success, alongside potential pressures from cost containment in healthcare and competitive pricing.

Key Highlights

1Launched the internally developed Express™ coronary stent in European and international markets in September 2001, with a U.S. launch anticipated for the second half of 2002.
2Made significant progress on the TAXUS™ drug-eluting coronary stent program, with early clinical trial results (TAXUS I) showing zero percent thrombosis and zero percent restenosis, and received FDA approval to initiate the TAXUS IV trial.
3Completed several strategic acquisitions in 2001 to broaden its technology portfolio, including Cardiac Pathways (electrophysiology), Catheter Innovations (venous access), Embolic Protection (embolic protection), Interventional Technologies (Cutting Balloon™), Quanam Medical (drug delivery), and RadioTherapeutics (oncology ablation).
4Invested approximately $275 million in research and development, representing about 10% of net sales, to fuel new product development, including the Express™ and TAXUS™ stent programs, and programs acquired through business combinations.
5Continued to expand its international presence, with international sales accounting for approximately 40% of net sales in 2001.
6Experienced a decline in sales of the NIR® coronary stent, with a 50% decrease in Q4 2001 compared to Q1 2001, anticipating continued market share decline due to physician acceptance erosion.

BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2001

Summary

Key Highlights

Frequently Asked Questions